Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138610 | 0.77 | ADRA2A (0.34) | — | |
| SCHEMBL370841 | 0.73 | TDP1 (0.35) | KCNH2MEN1KMT2A | |
| SCHEMBL28300226 | 0.72 | LIPG (0.38) | KCNH2MEN1KMT2A | |
| SCHEMBL1228572 | 0.72 | HCAR2 (0.37) | KCNH2 | |
| SCHEMBL28300224 | 0.72 | LIPG (0.38) | KCNH2MEN1KMT2A | |
| SCHEMBL574839 | 0.72 | HCAR2 (0.40) | MEN1KMT2A | |
| SCHEMBL5815987 | 0.72 | DHFR (0.40) | KCNH2MEN1KMT2A | |
| SCHEMBL20734522 | 0.72 | KCNH2 (0.37) | KCNH2MEN1KMT2A | |
| SCHEMBL27671187 | 0.72 | LIPG (0.38) | KCNH2MEN1KMT2A | |
| SCHEMBL20734524 | 0.70 | GPR84 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084486-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7960426-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7902232-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | ZOETIS SERVICES LLC | 2009-05-28 | — | — | US | disclosed |
| US-7514464-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1705989-B8 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| EP-1705989-B1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7435753-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| CN-101203134-A | Substituted arylpyrazoles as parasiticidal agents | PFIZER (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-100377645-C | Substituted arylpyrazoles as parasiticidal agents | PFIZER (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1901608-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| CN-1893825-A | Substituted arylpyrazoles as parasiticidal agents | PFIZER (US) | 2007-01-10 | — | — | CN | disclosed |
| WO-2006134466-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| EP-1705989-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| US-20060014802-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2006-01-19 | — | — | US | disclosed |
| US-20050148649-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2005-07-07 | — | — | US | disclosed |
| WO-2005060749-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | SPHK1 3914/4885KCNH2 1159/4885MEN1 3459/4885 |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | SPHK1 3914/4885KCNH2 1159/4885MEN1 3459/4885 |
| US-20050148649-A1 | Substituted arylpyrazoles | CYP3A4, CYP4B1, CYP1B1 | SPHK1 3600/4885KCNH2 1616/4885MEN1 1934/4885 |
| US-20060014802-A1 | Substituted arylpyrazoles | CYP4X1, ARG1, CYP2C9 | SPHK1 3092/4885KCNH2 1280/4885MEN1 3660/4885 |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A43, CYP3A4, CYP4X1 | SPHK1 2974/4885KCNH2 3028/4885MEN1 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.